Myqorzo Shines: Cytokinetics' Aficamten Delivers Hope for Non-Obstructive HCM Patients

There's genuinely exciting news bubbling up in the world of cardiology, particularly for those grappling with a challenging heart condition. Cytokinetics, a biopharmaceutical company, recently presented what can only be described as compelling full results from their ACACIA-HCM clinical trial for Myqorzo (aficamten). This medication is specifically aimed at adults living with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, and the findings suggest a real step forward. The data, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich and simultaneously published in the prestigious New England Journal of Medicine on August 28, 2026, certainly offers a significant glimmer of hope.

For those unfamiliar, hypertrophic cardiomyopathy (HCM) is a condition where the heart muscle becomes abnormally thick, making it harder for the heart to pump blood effectively. While Myqorzo has already made its mark in obstructive HCM (where the thickening blocks blood flow), this latest trial specifically focused on the "non-obstructive" form. Here, there isn't a physical obstruction, but patients still experience debilitating symptoms. Imagine the relief for patients who have few, if any, effective treatment options available to them; this trial’s success is a big deal.

Let's dive into what exactly these "compelling" results entail. The ACACIA-HCM trial met both of its primary endpoints with flying colors, showing statistically significant improvements compared to placebo at the 36-week mark. Patients treated with aficamten saw a 3.0-point greater improvement in their Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), a measure that really gets at how patients feel and function in their daily lives. Even more impressively, for those who stayed on treatment until 72 weeks, this advantage stretched to a substantial 7 points. Alongside this, there was a noticeable improvement in peak oxygen uptake (pVO₂), by 0.67 ml/kg/min, which is a key indicator of exercise capacity – meaning patients could do more without getting as breathless.

Beyond these main points, Myqorzo also demonstrated positive shifts across several important secondary endpoints. Things like an improvement in their NYHA (New York Heart Association) functional class, a composite CPET z-score, and a reduction in NT-proBNP levels (a biomarker often elevated in heart failure) all leaned favorably towards aficamten. What's truly encouraging is the overall picture of global efficacy: a remarkable 53% of patients on aficamten achieved a clinical response in three or more different outcome measures at 36 weeks, compared to just 13% on placebo. That’s a stark difference, isn't it?

Now, every medical breakthrough comes with its nuances, and Myqorzo is no exception. While generally well-tolerated, the trial did note higher rates of serious adverse events and heart failure in the aficamten group. For instance, 7.0% of aficamten patients discontinued due to non-fatal adverse events, compared to 1.9% on placebo. Serious adverse events occurred in 20.2% of the aficamten group versus 14.7% for placebo. Perhaps the most significant finding on the safety side was reversible reductions in left ventricular ejection fraction (LVEF) to less than 50% in 10.5% of aficamten patients (compared to 0.8% for placebo), with a small number (2.7%) seeing LVEF drop below 40%. A couple of patients even progressed to heart failure linked to the drug’s relaxing effect. It’s important to remember, though, that Myqorzo already carries a boxed warning and requires an FDA-mandated risk evaluation and mitigation strategy (REMS) from its earlier approval for obstructive HCM, so clinicians are well-versed in monitoring these aspects.

So, what’s next for Cytokinetics and Myqorzo? Building on these positive findings, the company plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026. They're seeking approval for Myqorzo to treat adult patients with symptomatic nHCM, which would be fantastic news. It’s worth noting that the drug has already received approval in the UK for obstructive HCM back in July 2026, signaling its potential global impact. The ACACIA-HCM trial itself was quite robust, enrolling 517 patients with symptomatic nHCM across 182 international sites, evenly randomized to receive either aficamten or a placebo. The patient demographic was pretty typical, with a mean age of 55.1 years and slightly more than half being women.

Of course, no trial answers every question perfectly. While the efficacy data is strong, the study didn't show a statistically significant difference in changes to left atrial volume index or the time to a first cardiovascular event. This means we don't yet have direct evidence of the drug impacting certain structural changes or "hard" clinical outcomes in this specific trial, though the improvements in symptoms and exercise capacity are undeniably valuable to patients' quality of life. Still, for many, the symptomatic relief and improved physical capabilities offered by Myqorzo would represent a profound change, offering a quality of life they perhaps hadn't dared to hope for.